Robert W. Baird reissued their outperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research report sent to investors on Tuesday morning. They currently have a $102.00 target price on the stock.

Other research analysts have also recently issued reports about the company. Jefferies Group set a $58.00 price target on Sarepta Therapeutics and gave the company a hold rating in a research note on Sunday, October 2nd. Oppenheimer Holdings Inc. reiterated an outperform rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 17th. RBC Capital Markets reiterated an outperform rating and issued a $106.00 price target (down from $108.00) on shares of Sarepta Therapeutics in a research note on Friday, October 28th. Wedbush reiterated an outperform rating and issued a $72.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 27th. Finally, William Blair upgraded Sarepta Therapeutics from a market perform rating to an outperform rating and set a $88.00 price target for the company in a research note on Monday, September 19th. One analyst has rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $66.28.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 36.72 on Tuesday. The firm has a 50-day moving average price of $43.01 and a 200-day moving average price of $31.71. The firm’s market capitalization is $2.00 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Thursday, October 27th. The company reported ($0.95) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.32) by $0.37. During the same period last year, the company posted ($1.25) earnings per share. Equities analysts expect that Sarepta Therapeutics will post ($4.31) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Sarepta Therapeutics Inc. (SRPT) Receives “Outperform” Rating from Robert W. Baird” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/30/sarepta-therapeutics-inc-srpt-receives-outperform-rating-from-robert-w-baird-2.html.

In related news, CEO Edward M. Md Kaye sold 40,179 shares of the company’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total value of $2,410,740.00. Following the completion of the transaction, the chief executive officer now directly owns 117,162 shares in the company, valued at $7,029,720. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sandesh Mahatme sold 30,000 shares of the company’s stock in a transaction on Monday, October 17th. The stock was sold at an average price of $50.08, for a total transaction of $1,502,400.00. Following the completion of the transaction, the insider now owns 61,532 shares of the company’s stock, valued at $3,081,522.56. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas raised its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Cornerstone Capital Management Holdings LLC. bought a new position in shares of Sarepta Therapeutics during the third quarter valued at about $140,000. Advisor Group Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter valued at about $154,000. Winslow Evans & Crocker Inc. bought a new position in shares of Sarepta Therapeutics during the third quarter valued at about $209,000. Finally, Quantitative Systematic Strategies LLC bought a new position in shares of Sarepta Therapeutics during the second quarter valued at about $211,000. Institutional investors own 76.99% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.